LLY Stock Price Today (October 2026) — Eli Lilly and Company Analysis & Key Metrics 2026-10-07
Eli Lilly and Company (LLY) is trading at $1188.72, up 2.70% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $1328.83 (11.8% upside).
- Volatility is low (18.39% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (47.70% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
LLY Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Eli Lilly and Company - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $1.11T
P/E Ratio
Forward P/E: 24.49
Revenue Growth
Year over Year
Analyst Target
+11.8% upside potential
Key Investor Questions About LLY
What investors need to know before buying
Based on current market data, LLY presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 62.39)
- Fundamentals say: Looking solid (debt and growth supportive)
LLY's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for LLY investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $54.91B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, LLY stock traded between $783.85 and $1292.65 and currently trades in the middle of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 18.39% annualized volatility and β=0.44, the stock exhibits low sensitivity to market moves—making LLY suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Eli Lilly (LLY) vs. Novo Nordisk (NVO): Has the GLP-1 Race Changed the Moat?
Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) were once viewed as the two big winners of the GLP-1 boom. However, the market’s view of the two companies has changed sharply. Since mid-2024, Novo’s stock has fallen roughly 74%, while Lilly’s has gained about 35%. That difference is also reflected in their valuations, […]
Eli Lilly (LLY) Wins Two FDA Approvals And A $3.35 Billion Drug Alliance
Eli Lilly (NYSE:LLY) received FDA approval for Olumiant to treat pediatric patients with severe alopecia areata. The FDA also cleared once weekly insulin Onswik for adults with type 2 diabetes, adding a new dosing option. Eli Lilly agreed a global drug discovery alliance with InnoCare Pharma valued at up to US$3.35b in research and licensing commitments. These combined FDA approvals and the US$3.35b InnoCare alliance deserve weighing against the rest of our Eli Lilly analysis. We have also...
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.
Is LLY Stock Cheaper Than It Looks?
At about $1,182 a share, Eli Lilly (LLY) stock trades at about 33.1 times trailing earnings. Those are adjusted earnings: normalized net income with stock-based compensation added back, a basis built to sit close to the one analysts use in their forecasts. That looks expensive. Whether it is depends on two obesity drugs, on margins and on how much Lilly spends buying new medicines.
Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case
All three major US stock indexes were edging higher in midday trading Friday as Treasury yields rema
Obesity titan could shake up Lilly and Novo after astonishing trial
The San Diego company’s flexible dosing results could carve out real market share in the obesity drug race.
VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?
Obesity specialist Lou Aronne said switching from a GLP-1 drug to a dual GLP-1/GIP drug could mean greater weight loss.
Eli Lilly CEO reveals astonishing shift in GLP-1 pill market
Medicare coverage opens the obesity pill market to millions more Americans.
Lilly Rises Higher as Viking Preserves Up to 90% Monthly
Less-frequent injections could challenge chronic-treatment economics long before Viking reaches the market.
Should Eli Lilly (LLY) Investors Watch Its $6.5 Billion Houston GLP 1 Buildout?
Eli Lilly (NYSE: LLY) has started construction on a US$6.5b manufacturing facility in Houston to produce its oral GLP-1 drug Foundayo. The new site is focused on supplying Foundayo for obesity treatment as demand for oral GLP-1 therapies grows in the US and abroad. The project includes partnerships for local workforce training in Houston to support specialized pharmaceutical manufacturing roles. This large Houston buildout for Foundayo is an important piece to weigh alongside the rest of our...
Explore More Analysis for LLY
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 29, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Eli Lilly and Company
Eli Lilly and Company (LLY) is currently trading at $1188.72. The RSI (14-day) is at 62.4, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $1328.83 implies 11.8% upside from current levels. Volatility is low at 18.4% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Eli Lilly and Company (LLY): The trailing P/E ratio is 38.74, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 24.49, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.48, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 29.95. Price-to-Sales is 12.74. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering LLY, the consensus price target is $1328.83. This represents a 11.8% upside from the current price of $1188.72. The range spans from a low target of $930.00 to a high target of $1600.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Eli Lilly and Company (LLY) pays a dividend with a current yield of approximately 0.58%. The annualized dividend rate is $6.46 per share. The payout ratio is 21.7%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Aug 14, 2026.
Key risks for Eli Lilly and Company (LLY) investors include: 1. Elevated debt levels (debt-to-equity of 1.62x) which could pressure margins in a rising rate environment. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Eli Lilly and Company's (LLY) current debt and financial health profile: Total debt stands at $54.91B. The debt-to-equity ratio is 1.62x, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.36, indicating adequate short-term liquidity. The quick ratio is 0.68. The company holds $8.95B in cash and equivalents. Free cash flow is positive at $11.07B, providing a cushion for debt servicing and shareholder returns.